Investors should monitor upcoming Phase 2b data readouts as key catalysts; positive results could validate KT-621 as a best-in-class oral therapy for Type 2 inflammation, supporting premium valuation ahead of pivotal trials.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 30 $79.48entry
- T+1 · 8mo ago +4.79%α +1.90% · $83.29
- T+5 · 7mo ago +7.07%α +2.77% · $85.10
- T+20 · 7mo ago +5.50%α −7.10% · $83.85
- T+60 · 5mo ago +46.53%α +30.04% · $116.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kymera Therapeutics announced positive Phase 1b trial results for KT-621, an oral STAT6 degrader, showing deep target degradation and encouraging clinical activity in patients with moderate-to-severe atopic dermatitis. The data support further development in ongoing Phase 2b trials, with readouts expected by mid-2027 and late-2027.
Key Facts
- KT-621 demonstrated 94% median STAT6 degradation in skin and 98% in blood after 28 days of dosing.
- Robust biomarker reductions: 74% median TARC reduction, up to 73% Eotaxin-3, 56% IL-31, and 14% IgE.
- Clinical improvements: 63% mean EASI reduction, 29% achieved EASI-75, 19% reached vIGA-AD 0/1, 40% peak pruritus NRS reduction.
- KT-621 was well tolerated with a favorable safety profile.
- Phase 2b trials (BROADEN2 in AD, BREADTH in asthma) ongoing; data expected mid-2027 and late-2027.
Financial Impact
No direct financial impact reported; potential long-term value creation if Phase 2b trials confirm efficacy.
Risk Factors
- Phase 1b results may not be predictive of Phase 2b or Phase 3 outcomes.
- Competition from established biologics (e.g., dupilumab) and emerging oral agents in atopic dermatitis.
- Dilution risk from future capital raises to fund advancing clinical programs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264183 |
Track record
37 reports on KYMR
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 8 of 13 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers